Want to see AU:ANR full AI Analyst Report?
ANR Stock Chart & Stats
AU$0.01
<AU$0.01(3.85%)
At close: 4:00 PM EST
AU$0.01
<AU$0.01(3.85%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.02
Previous CloseN/A
Volume35.84K
Average Volume (3M)759.89K
Market Cap
AU$3.16M
Enterprise ValueAU$1.20M
Total Cash (Recent Filing)AU$1.09M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding315,950,780
10 Day Avg. Volume1,527,300
30 Day Avg. Volume759,886
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)1.91
Price to Sales (P/S)1.06
P/FCF Ratio-0.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue ReboundA ~287% YoY revenue rebound to ~0.97M indicates emerging commercial traction for product candidates. Sustained top-line growth over several quarters would validate market demand, improve negotiating leverage for partners, and create a foundation for scaling if margins and cash generation are addressed.
Focused Product StrategyA clear, narrow focus on orally delivered gastrointestinal health products creates specialization advantages: targeted R&D, regulatory pathways, and partner alignment. This structural positioning supports repeatable development processes and clearer commercial partnership opportunities over the medium term.
Smaller Net Loss Vs Prior YearsA reduction in net loss versus earlier years signals progress in cost control or revenue mix improvements. If sustained, this trend can extend runway efficiency, reduce future financing needs, and indicate management is moving toward operational scalability and eventual path to profitability.
Bears Say
Negative Gross MarginsNegative gross margins mean core product economics do not cover direct costs, so increasing sales can widen losses unless unit costs fall or pricing improves. This undermines long-term scalability because revenue growth alone won't translate to sustainable profits without structural cost or product changes.
Worsening Cash BurnConsistently negative operating and free cash flow with accelerating burn reduces runway and forces reliance on external capital. Over 2-6 months this increases the probability of dilutive funding or restrictive credit, constraining R&D and commercialization timelines and shareholder value retention.
Deteriorating Balance-sheet FlexibilityRising leverage and sharply lower equity reduce financial flexibility to absorb setbacks or fund growth. Higher debt obligations and shrinking equity increase refinancing risk and may hamper strategic options like partnerships or supply agreements over the coming months.
Anatara Lifesciences Ltd News
ANR FAQ
What was Anatara Lifesciences Ltd’s price range in the past 12 months?
Anatara Lifesciences Ltd lowest share price was <AU$0.01 and its highest was AU$0.02 in the past 12 months.
What is Anatara Lifesciences Ltd’s market cap?
Anatara Lifesciences Ltd’s market cap is AU$3.16M.
When is Anatara Lifesciences Ltd’s upcoming earnings report date?
Anatara Lifesciences Ltd’s upcoming earnings report date is Aug 26, 2026 which is in 20 days.
How were Anatara Lifesciences Ltd’s earnings last quarter?
Anatara Lifesciences Ltd released its earnings results on Feb 25, 2026. The company reported -AU$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.002.
Is Anatara Lifesciences Ltd overvalued?
According to Wall Street analysts Anatara Lifesciences Ltd’s price is currently Overvalued.
Does Anatara Lifesciences Ltd pay dividends?
Anatara Lifesciences Ltd does not currently pay dividends.
What is Anatara Lifesciences Ltd’s EPS estimate?
Anatara Lifesciences Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Anatara Lifesciences Ltd have?
Anatara Lifesciences Ltd has 315,950,780 shares outstanding.
What happened to Anatara Lifesciences Ltd’s price movement after its last earnings report?
Anatara Lifesciences Ltd reported an EPS of -AU$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Anatara Lifesciences Ltd?
Currently, no hedge funds are holding shares in AU:ANR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Anatara Lifesciences Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:ANR Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
―
20 days / 200 days
Momentum
-79.31%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-24.67%
Trailing 12-Months
Company Description
Anatara Lifesciences Ltd
Anatara Lifesciences Ltd is an Australian enterprise focused on researching, developing, and commercializing scientifically-validated therapies for digestive system ailments affecting both humans and animals. Its product portfolio includes Gastrointestinal ReProgramming (GRP), a proprietary blend combining bromelain with other evidence-based ingredients, specifically formulated to target the underlying issues of human gastrointestinal conditions such as irritable bowel syndrome and inflammatory bowel disease. The firm also offers 3FDC, designed to address anxiety, stress, or depression. In the animal health sector, Anatara provides Detach for treating diarrhea in piglets, BONIFF as an enhanced dry feed formulation for weaned piglets, and ANR-pf, a unique additive for poultry drinking water. This company was founded in 2010 and is headquartered in Carlton, Australia.
Technical Analysis
Immuron Limited
―
Botanix Pharmaceuticals Limited
―
EZZ Life Science Holdings Ltd.
―
Biome Australia Ltd
―
Recce Pharmaceuticals Ltd.
―